Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Ordinary Shares, no par value per share
-
Shares outstanding
-
112,245,592
-
Total 13F shares
-
90,419,824
-
Share change
-
+1,319,072
-
Total reported value
-
$3,752,040,945
-
Put/Call ratio
-
34%
-
Price per share
-
$41.50
-
Number of holders
-
255
-
Value change
-
+$42,388,515
-
Number of buys
-
102
-
Number of sells
-
149
Institutional Holders of NovoCure Ltd - Ordinary Shares, no par value per share (NVCR) as of Q2 2023
As of 30 Jun 2023,
NovoCure Ltd - Ordinary Shares, no par value per share (NVCR) was held by
255 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
90,419,824 shares.
The largest 10 holders included
FMR LLC, Capital World Investors, VANGUARD GROUP INC, Capital International Investors, BAILLIE GIFFORD & CO, BlackRock Inc., PRICE T ROWE ASSOCIATES INC /MD/, STATE STREET CORP, T. Rowe Price Investment Management, Inc., and Nordwand Advisors, LLC.
This page lists
255
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.